13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Sponsors
Walvax Biotechnology Co., Ltd., CanSino Biologics Inc., Wuhan BravoVax Co., Ltd., Shanghai Reinovax Biologics Co.,LTD
Conditions
Bacterial InfectionsDiseases Caused by Streptococcus Pneumoniae SerotypesPneumococcal InfectionsPneumococcal Infectious DiseaseStreptococcal Infections
Phase 1
Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above
CompletedNCT04100772
Start: 2020-05-18End: 2022-08-23Updated: 2022-10-31
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
NCT05602480
Start: 2022-11-01End: 2024-12-31Target: 264Updated: 2022-11-17
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Active, not recruitingNCT06675032
Start: 2024-04-27End: 2026-03-31Target: 230Updated: 2025-12-26
Phase 3
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
CompletedNCT02736240
Start: 2016-04-08End: 2017-12-03Updated: 2020-10-14
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
CompletedNCT04841369
Start: 2021-04-13End: 2022-09-20Updated: 2024-04-02